Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsIn this review, Dong et al. compiled the current understanding of IL-12 in cancer immunotherapy. The focus of the review is on different strategies being employed to deliver IL-12 to increase its efficacy and safety. Overall, the review is well-structured and offers valuable insights into the current state of knowledge in this field. The following are some comments that need the authors' attention:
A) It would be more informative if the current status of the drug/therapy could be mentioned in each table, i.e., whether it is under clinical trial or not, and the trial stage, etc.
B) Page 2, paragraph 2: Write the full form of the term "TKI" because it is used for the first time here. Similarly, in some other places, abbreviations are used directly without providing the full names first. For example, on page 5, paragraph 1: What "OV" refers to is not explained.
C) In several places, proper background information/introduction is missing before introducing a new concept. For example, on page 3, paragraph 3: G47Δ-mIL12 and G47Δ were mentioned without providing enough information about what the G47Δ mutation is, how it is connected to HSV, and why it is important.
D) Lastly, there are several grammatical and typographical errors throughout the manuscript, and careful reading and corrections are required. For example: Page 1: "Instruction" heading; Page 3, paragraph 2: "T-ECV"; Page 11, paragraph 2: "antigen-presenting molecule (APC)."
Comments on the Quality of English LanguageI have provided my comments on the English in the main comments.
Author Response
Please see the attachment
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsThis manuscript provides a comprehensive review of different strategies to delivery IL-12 for tumor immunotherapy with a variety of examples. Overall, the quality of the manuscript is good since it’s very organized and clear. However, as a review paper, there should be more insightful discussion comparing different methods. Therefore, I recommend this manuscript be reevaluated after minor revision. Here are some recommendations:
1. Since this manuscript mainly discusses delivery strategies, I recommend changing the title to something like “ current delivery strategies for IL-12 in tumor immunotherapy” to enable readers to gain a more specific preview of the paper content.
2. In section 4, the conclusion and future direction is too general. Adding more specific and systematic discussions comparing different delivery strategies will provide more insights for the field. A summary table of the pros and cons of major strategies will guide researchers in choosing the most appropriate method for IL-12 delivery.
3. A summary figure explaining the different delivery mechanisms and resulting therapeutic effects should be supplied in the introduction part.
4. For Table 11, it will be more informative to add the cell type information.
Minor issues:
1. The formatting of some subtitles is not consistent. For instance, in section 2.3.1, there is an indentation for “polymer-based nanoparticles”, which is not present in “Dendritic Cells” when discussing cell-based methods.
2. Some words are mistakenly capitalized. For example, “Colon cancer” in the second paragraph of “Dendritic Cells” section.
Author Response
Please see the attachment
Author Response File: Author Response.pdf
